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Abstract In the latest years, innovative nanomaterials
have attracted a dramatic and exponentially increasing
interest, in particular for their potential applications in the
biomedical field. In this paper, we reported our findings on
the cytocompatibility of barium titanate nanoparticles
(BTNPs), an extremely interesting ceramic material. A
rational and systematic study of BTNP cytocompatibility
was performed, using a dispersion method based on a non-
covalent binding to glycol-chitosan, which demonstrated
the optimal cytocompatibility of this nanomaterial even at
high concentration (100 lg/ml). Moreover, we showed that
the efficiency of doxorubicin, a widely used chemotherapy
drug, is highly enhanced following the complexation with
BTNPs. Our results suggest that innovative ceramic
nanomaterials such as BTNPs can be realistically exploited
as alternative cellular nanovectors.
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Introduction
Delivery systems for therapeutics range from liposomal
complexes to particles made up of various materials,
including ceramics, polymers and metals [1–3]. Among the
chemotherapy drugs, there has been an extensive interest for
doxorubicin [4], a cytotoxic anthracycline antibiotic that
works by intercalating with DNA to interfere with nucleic
acid synthesis, producing a marked effect on cells in the S
phase of cell cycle and affecting DNA transcription [5].
Moreover, doxorubicin is a fluorescent molecule with a
chromophore group composed of three planar and aromatic
hydroxyanthraquinonic rings, and its intrinsic fluorescence
is exploited to monitor its accumulation in living systems [6].
Although used frequently, a major problem associated
with doxorubicin administration involves its side effects, in
particular concerning cardiac function, myelosuppression,
alopecia and hepatic toxicity [7–9]. Interesting advances to
reduce side effects involved the development of a targeted
approach to chemotherapy through a liposomal system,
available as Doxil [10]. However, its safety has constantly
been under investigation due to the adverse side effects still
experienced by patients [11, 12]. Thus, there is still necessity
for the development of improved systems for doxorubicin
administration [13–16].
In this paper, we described an alternative and previously
unreported supramolecular complexation of doxorubicin
with a ceramic nanomaterial, barium titanate nanoparticles
(BTNPs), that might be exploited for cancer therapy.
Ceramic materials based on perovskite-like oxides are of
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intense interest because of their applications in electrical
and electronic devices [17]. Due to its high dielectric
constant, barium titanate (BaTiO3) is probably one of the
most studied compounds of this family [18]. No evidence
of bio-applications of this nanomaterial has been found in
the literature to our knowledge, so we first proposed a
preliminary in vitro investigation into cytocompatibility
and cell interactions of barium titanate nanoparticles [19].
Here, we introduced two non-covalent functionalizations of
the nanoparticles (Fig. 1): with (1) glycol-chitosan and (2)
doxorubicin.
Glycol-chitosan dispersion is essential to evaluate the
cytocompatibility of the nanoparticles not associated with
the drug. A polymer wrapping is a useful and effective
method to have samples suitable for biological testing,
being barium titanate strongly hydrophobic. To this scope,
glycol-chitosan, a biopolymer already widely used in the
biomedical field [20–22], resulted an excellent solution. As
a dispersing agent of absolute biocompatibility [23], gly-
col-chitosan allowed us to drastically increment the tested
concentration of nanoparticles with respect to our previous
study, which was performed using poly-L-lysine [19], thus
enabling a systematic and rational investigation into cyto-
toxicity to be performed in a wide range of concentrations
(0–100 lg/ml) and throughout several complimentary
assays (MTT, Live/Dead, apoptosis and ROS detection).
As a second step, a complexation of BTNPs with
doxorubicin was performed that allowed, after adminis-
tration to neuroblastoma SH-SY5Y cells, a statistically
significant increment of the cellular internalization of this
drug to be revealed. An increased drug uptake mediated by
BTNP nanovectors indicates, at least theoretically, that a
reduced dose can be administered, maintaining unaltered
the efficiency of the treatment. These results seem to be
strictly correlated with the high propensity of BTNPs to be
internalized by the cells, as demonstrated by TEM analysis,
and thus to a more efficient uptake of the drug, that is non-
covalently complexed to the nanoparticles.
Materials and Methods
Cytocompatibility Testing
Preparation of the Samples
Barium titanate nanoparticles (BTNPs) were purchased
from Nanostructured & Amorphous Materials, Inc.
(Houston, TX). Details of sample purity and composition,
as provided by the supplier, include yield 99%; BaO/TiO2:
0.999–1.001; purity: 99.9%; APS: 100 nm (from scanning
electron microscope); SSA: 10–11 m2/g; color: white;
morphology: spherical and true density: 5.85 g/cm3. After
purchasing, BTNP samples were further analyzed in order
to show additional characterization. The energy dispersive
X-ray analysis [19] confirmed the data provided by the
supplier, and no significant impurities were detected by the
micro-analysis, with a relative quantitative composition as
following: Ba * 60%, Ti * 18% and O * 22%.
Since pristine dry samples of BTNPs appeared as
strongly hydrophobic large aggregates, cytocompatibility
evaluation was performed after stabilization in an aqueous
environment thanks to a non-covalent wrapping with gly-
col-chitosan (GC; G7753 from Sigma). Dispersions were
prepared with phosphate-buffered saline (PBS) solution.
Nanoparticles (10 mg) were mixed with 10 ml of a 1 mg/
ml GC solution in a polystyrene tube. The samples were
sonicated for 12 h (by a Bransonic sonicator 2510) using an
output power of 20 W for all the experiments, resulting in a
stable GC–barium titanate nanoparticle (GC–BTNP) dis-
persion by the non-covalent coating with GC (1 mg/ml GC
and 1 mg/ml BTNP, 1:1 w/w). Microphotographs of the
final dispersion of GC–BTNPs were obtained via both
focused ion beam microscopy (FIB, FEI 200) and trans-
mission electron microscopy (TEM, Zeiss 902), pipetting a
small quantity of a GC–BTNP aqueous sample on a copper
grid and let it dry in a 37C oven.
Particle size distribution of the dispersions was analyzed
with a Nano Z-Sizer 90 (Malvern Instrument); each
acquisition was performed three times, on samples appro-
priately diluted in PBS.
Cytocompatibility assays were performed using a
human neuroblastoma SH-SY5Y cell line (CRL-2266
Cytocompatibility 
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Fig. 1 Schema of the preparation of the BTNPs for biological testing
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from ATCC). Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) and Ham’s F12 (1:1 volume
ratio) with 10% fetal bovine serum (from ATCC),
100 IU/ml penicillin, 100 lg/ml streptomycin and
2 mM L-glutamine. Cells were maintained at 37C in a
saturated humidity atmosphere containing 95% air/5%
CO2.
MTT Assay
For viability testing, 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT; M2128 from Sigma)
cell proliferation assays were carried out. After trypsin-
ization and counting with a hemocytometer, 5,000 cells
were seeded in 96-well plate chambers. Once adhesion was
verified (about 12 h after seeding), cells were incubated
with 0, 5, 10, 20, 50 and 100 lg/ml of GC–BTNPs for
48 h. At each endpoint, cultures were incubated with MTT
at 0.5 mg/ml for further 4 h, followed by addition of
dimethyl sulfoxide (DMSO; D8418 from Sigma) at 100 ll/
well for cell lysis. Then, absorbance was measured with a
microplate reader (Victor3, Perkin Elmer) at 550 nm.
Appropriate controls were performed by incubating cells
with the corresponding concentrations of glycol-chitosan,
but without BTNPs.
Viability/Cytotoxicity Test
Cell viability was further investigated with the LIVE/
DEAD viability/cytotoxicity test (Molecular Probes). The
kit contains calcein AM (4 mM in anhydrous DMSO) and
ethidium homodimer-1 (EthD-1, 2 mM in DMSO/H2O 1:4
v/v). After incubation for 48 h at a GC–BTNP concentra-
tion ranging in 0–100 lg/ml, cells (30,000 in 24-well plate
chambers, n = 3) were rinsed with PBS and treated for
10 min at 37C with 2 lM calcein AM and 4 lM EthD-1
in PBS. Cultures were finally observed with an inverted
fluorescence microscope (TE2000U, Nikon) equipped with
a cooled CCD camera (DS-5MC USB2, Nikon) and with
NIS Elements imaging software, equipped with the
appropriate filters.
Live cells can be distinguished from dead ones due to
the presence of ubiquitous intracellular esterase activity,
determined by the enzymatic conversion of the non-fluo-
rescent cell-permeant agent, calcein AM, to an intensely
fluorescent molecule, calcein. Calcein is well retained
within live cells, producing an intense uniform green
fluorescence. Conversely, EthD-1 enters cells with dam-
aged membranes and undergoes a strong fluorescence
enhancement upon binding to nucleic acids, thereby pro-
ducing a bright red fluorescence in dead cells. EthD-1 is
excluded by the intact plasma membrane of live cells.
Early Apoptosis Detection
Apoptosis plays a fundamental role in many normal bio-
logical processes as well as in several diseased states of
cells and can be induced by various stimuli that will further
result in systematic cell death. One of the methods
employed to study apoptosis detects changes in the position
of phosphatidylserine (PS) in the cell membrane. In non-
apoptotic cells, most PS molecules are localized on the
inner layer of the plasma membrane, but soon after the
initiation of apoptosis, PS is redistributed to the outer layer
of the membrane and becomes exposed to the extracellular
environment [24]. Exposed PS can be easily detected using
annexin V, a 35.8-kDa protein with strong affinity for PS.
For early apoptosis detection, 30,000 cells were seeded
in 24-well plate chambers (n = 3) and treated with 0–
100 lg/ml of GC–BTNPs for 48 h. ApoAlert kit (Clone-
tech Laboratories) was used to evaluate differences
between normal and apoptotic cells after treatments. The
kit contains annexin V-FITC (20 lg/ml in Tris-NaCl), 19
binding buffer and propidium iodide (PI; 50 lg/ml in 19
binding buffer). Cells were rinsed with 19 binding buffer
and then incubated with 200 ll of 19 binding buffer
containing 5 ll of the annexin V solution and 10 ll of the
PI solution; then, 5 lg/ml of Hoechst 33342 (H1399 from
Invitrogen) was used for nucleus staining (blue). After
incubation in the dark at room temperature for 20 min,
cells were observed via fluorescence microscopy with the
appropriate filters.
The combination of annexin V-FITC with PI, a red
fluorescent DNA-intercalating agent excluded by viable
cells, allows necrotic (red stained), early apoptotic (green
stained), apoptotic (green and red stained) and normal cells
(unstained) to be identified.
Reactive Oxygen Species Detection
Generation of reactive oxygen species (ROS) is a normal
event for aerobic organisms, and, in healthy cells, occur-
ring at a controlled rate. Under conditions of oxidative
stress, like exposure to nanomaterials [25], ROS production
is dramatically increased, resulting in subsequent alteration
of membrane lipids, proteins and nucleic acids.
ROS production in SH-SY5Y cells treated with GC–
BTNPs was detected using the Image-IT Green Reactive
Oxygen Species Detection kit (Invitrogen). The assay is based
on 5-(and-6)-carboxy-20,70-dichlorodihydrofluorescein diac-
etate (carboxy-H2DCFDA), a fluorogenic marker for ROS in
viable cells. The non-fluorescent carboxy-H2DCFDA per-
meates live cells and is deacetylated by non-specific intra-
cellular esterases. In the presence of non-specific ROS
(produced throughout the cell, particularly during oxidative
stress), the reduced fluorescein compound is oxidized and
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emits bright green fluorescence [26]. Cells (30,000 per well)
were seeded in 24-well plate chambers (n = 3) and treated
with 0–100 lg/ml of GC–BTNPs for 48 h. Thereafter, they
were incubated for 45 min with a 25 lM carboxy-
H2DCFDA working solution (in DMSO:PBS at 1:400 v/v)
and immediately observed via fluorescence microscopy with
the appropriate filters. During the last 5 min of incubation,
cell nuclei were blue stained with 5 lg/ml of Hoechst 33342.
Doxorubicin Complexes Testing
Preparation of the Samples
Complexes between doxorubicin and barium titanate
nanoparticles were prepared by mixing 10 mg of nano-
particles with 10 ml of a 100 lg/ml aqueous solution of
doxorubicin (D1515 from Sigma) followed by sonication
of the resulting dispersion for 6 h, as described for the GC–
BTNP preparation. The final product is a stable dispersion
of BTNPs in doxorubicin (Dox-BTNPs), having concen-
trations of 1 mg/ml and 100 lg/ml of BTNPs and Dox,
respectively. The obtained dispersion was characterized by
spectrophotometric analysis, using a LIBRA S12 Spectro-
photometer UV/Vis/NIR (Biochrom). Particle size distri-
bution was analyzed as previously described.
MTT Assay
MTT assays, carried out as previously reported, were
performed after incubating cell samples (5,000 in 96-well
plate chambers, n = 6) for 24 h at different concentrations
of either Dox-BTNPs or Dox alone. Table 1 summarizes
the performed tests that are identified with K, A, B, C and
D, for increasing concentration of Dox-BTNPs. In each
test, the ratio doxorubicin:nanoparticles was maintained
constant (1:10 w/w), and a respective control with doxo-
rubicin alone (not complexed with the BTNPs) was
performed.
Dox-BTNP Uptake: Fluorescence Analyses
Cells were treated as reported in previous section for MTT
assay. At the endpoint, cultures (n = 6) were rinsed three
times in PBS and thereafter treated with 100 ll of a 1%
Triton X-100 solution (T9284 from Sigma) for 30 min at
37C. Once complete cell lysis was verified, the sample
was transferred in a black 96-well plate for fluorescence
measurement on a Victor3 (Perkin Elmer) microplate
reader, equipped with the appropriate filters for doxorubi-
cin detection (Ex 485 nm, Em 572).
Cell cultures incubated for 24 h with different concen-
trations of Dox-BTNPs (and doxorubicin alone as controls)
were also imaged with fluorescence microscope.
Dox-BTNP Uptake: TEM Analysis
Internalization of the Dox-BTNP complexes was assessed
by TEM. SH-SY5Y cells were seeded at 2 9 106 cells/T25
flask. After adhesion, cell samples were incubated with a
Dox-BTNP-modified culture medium (at final concentra-
tions of Dox 1.5 lg/ml and BTNP 15 lg/ml). After a 24-h
incubation, samples were washed in PBS 0.1 M, trypsini-
zed and thereafter fixed with 1% w/v glutaraldehyde—4%
w/v paraformaldehyde in PBS 0.1 M pH 7.2 for 2 h at 4C.
After washing, the cells were post-fixed in 1% w/v OsO4
PBS 0.1 M pH 7.2 for 1 h, washed and dehydrated with
acidified aceton-dimethylacetal (Fluka) for 10 min. Thus,
the samples were mixed in Epon/Durcupan resin in BEEM
capsules (#00 from Structure Probe) overnight at room
temperature and finally embedded in resin at 56C for 48 h.
Ultrathin sections (20–30 nm thick) were obtained with an
Ultrotome Nova ultramicrotome (LKB, Bromma, Sweden)
equipped with a diamond knife (Diatome, Biel/Bienne,
Switzerland). The sections were placed on 200-square
mesh nickel grids, counterstained with saturated aqueous
uranyl acetate and lead citrate solutions and observed in a
Zeiss 902 transmission electron microscope.
Statistical Analysis
Analysis of data was performed by analysis of variance
(ANOVA) followed by Student’s t-test to test for signifi-
cance which was set at 5%. MTT and fluorescence tests
were performed in esaplicate; all other assays in triplicate.
In all cases, three independent experiments were carried
out. Results are presented as mean value ± standard error
of the mean.
Table 1 Summary of the experiments performed on SH-SY5Y with
Dox–BTNP complexes and respective controls
Test Concentrations (lg/ml)
[Dox] [BTNP]
K Dox 0 0
Dox–BTNP 0 0
A Dox 0.5 0
Dox–BTNP 0.5 5
B Dox 1 0
Dox–BTNP 1 10
C Dox 1.5 0
Dox–BTNP 1.5 15
D Dox 2 0
Dox–BTNP 2 20
For each experiment, concentration of drug and nanoparticles is
provided
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Results and Discussion
Evaluation of Cytocompatibility of Glycol-chitosan-
Coated Barium Titanate Nanoparticles (GC–BTNPs)
Imaging of the GC–BTNPs by FIB microscopy and TEM
revealed well-dispersed structures (Fig. 2a, b), whose sizes
were in fully agreement with those obtained by dynamic
light scattering analysis, the latter providing a size value of
about 285 nm (poly-dispersity index 0.180). After prepa-
ration, GC–BTNP dispersions resulted stable for many
days, and even if some visible aggregates appeared after 1–
2 weeks, they resulted completely dissolvable after a mild
sonication (30 min). The dispersions were thereafter
appropriately diluted in culture medium for cytocompati-
bility assessment.
MTT provided an excellent metabolic activity in cells
treated up to 100 lg/ml of GC-BTNPs, with a slight
decrement in viability at 50 and 100 lg/ml (about 5 and
10%, respectively), from the control, that was not statisti-
cally significant in both cases (p [ 0.05) (Fig. 3).
Cell viability was further investigated with the LIVE/
DEAD viability/cytotoxicity test. Also in this case, the
compatibility of GC–BTNPs resulted excellent at each
tested concentration (Fig. 4). Absence of cell membrane
damage could be detected following cell treatment up to
100 lg/ml of GC–BTNPs, which clearly demonstrates an
optimal cell viability, completely comparable to that of the
control cultures.
Absence of significant apoptotic phenomena (Fig. 4)
was also verified with the annexin V test, and no evidence
of apoptosis was observed in all the treated samples. Only a
few dead cells could be observed in the sample treated with
GC–BTNPs at the highest concentration (100 lg/ml), in
agreement with the previous assays.
Finally, ROS production in SH-SY5Y cells treated with
GC–BTNPs was analyzed. As shown in Fig. 4, GC–BTNPs
do not induce significant oxidative stress after 48-h
Fig. 2 FIB (a, c) and TEM (b, d) imaging of GC–BTNPs (a, b) and of Dox–BTNPs (c, d)
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Fig. 3 MTT assay results for increasing GC–BTNPs concentrations
and for the respective controls (GC alone)
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incubation, even at high concentrations, and just a few
green-fluorescent cells could be detected at 100 lg/ml
concentration, consistent with all the previous cytocom-
patibility data.
Evaluation of the Efficiency of Dox–BTNP Complexes
Dispersions of BTNPs inside doxorubicin aqueous solutions
obviously resulted less stable than those in glycol-chitosan,
in particular because of the difference in molecular weight
between the polymer and the drug, and therefore of the
hydrophobic interactions that stabilize the nanoparticles.
Dynamic light scattering analysis showed a bimodal distri-
bution of the sizes, with a first peak around 300 nm (about
20% of the intensity) and a second peak around 2 lm (about
80% of the intensity), denoting the formation of relatively
larger aggregates in solution, not directly observable with the
FIB (Fig. 2c) and TEM (Fig. 2d) imaging.
Live/dead Apoptosis ROS production
0
µg/ml
5
µg/ml
10
µg/ml
20
µg/ml
50
µg/ml
100
µg/ml
[BTNPs]
40 µm
Fig. 4 Summary of the results
of the viability/cytotoxicity
assay, early apoptosis detection
and ROS detection following
incubation with increasing GC–
BTNPs concentrations
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Spectrophotometric analysis of the Dox–BTNPs,
reported in Fig. 5, confirmed a non-covalent complexation
between the doxorubicin and the drug, and spectrum fea-
tures of doxorubicin are maintained and superposed to the
BTNP absorbance, keeping the characteristic peak at
490 nm.
The presence of microaggregates did not prevent the in
vitro evaluation of the Dox–BTNP complexes from
occurring. Analysis was performed on SH-SY5Y cells at
four concentrations, as outlined in Table 1.
Results of Test A in treated samples did not differ from
those in the control cultures. Cells treated with either
doxorubicin alone (500 ng/ml) or doxorubicin complexed
with BTNPs (Dox–BTNPs) at a concentration of 5 lg/ml
did not reveal any appreciable decrement in viability
(p [ 0.1) with respect to the controls (test K). Tests B and
C provided more interesting results. While doxorubicin
alone at the tested concentrations (1 and 1.5 lg/ml, in Tests
B and C, respectively) did not show any effects on the
neuroblastoma cell proliferation with respect to the con-
trols (p [ 0.1), when it was combined with BTNPs, the
drug efficiency resulted significantly enhanced. Cell via-
bility measured with MTT test achieved a inhibition of
about 15% and 20% for concentrations of 10 and 15 lg/ml
of Dox-BTNP complexes, respectively (in both cases
p \ 0.05). Also in Test D, we noticed a strong increment
(p \ 0.005) in the toxic effects of doxorubicin when
combined with the BTNPs (20 lg/ml), although, in this
case, also doxorubicin alone (2 lg/ml) was able to con-
siderably inhibit the cell proliferation (p \ 0.05).
This inhibition increment in cell proliferation in the case
of doxorubicin associated with the BTNPs (Fig. 6a) cannot
be attributed to a combined toxic effect of nanoparticles
and drugs, since in this report we demonstrated the absolute
cytocompatibility of the nanoparticles up to a concentration
of 100 lg/ml. We can thus hypothesize that the non-
covalent complexation of doxorubicin with a nanoparticu-
late system allows an enhancement of the internalized
drug, thanks to a strong uptake of BTNPs by the cells. We
therefore investigated the doxorubicin internalized by the
cells exploiting the intrinsic fluorescence of this molecule.
Cell lysates of the cultures of Test K, A, B, C and D were
analyzed at appropriate fluorescence wavelengths, and the
results are reported in Fig. 6b. The fluorescence values are
in agreement with the MTT assay: in Test A, we did not
observe an appreciable presence of drug internalized by the
cells, while Test B revealed a statistically significant inter-
nalization of doxorubicin (about 40% increment in fluo-
rescence, p \ 0.05) when doxorubicin (1 lg/ml) is
combined with the nanoparticles (10 lg/ml). Internalization
of doxorubicin alone, at this concentration, is negligible
(p [ 0.05). Tests C and D confirmed a strong internaliza-
tion of the drug, at both concentrations (1.5 and 2 lg/ml,
respectively, p \ 0.05 calculate with respect to the control),
that is much more enhanced by the complexation with the
nanoparticles: in Test C the uptake increment of drug fol-
lowing incubation with Dox–BTNPs was about 80%
(p \ 0.05), while in Test D it was about 40% (p \ 0.05).
These quantitative results were confirmed by fluorescent
microscopy. Figure 7 shows cell culture images of Test C:
Fig. 7a depicts a culture incubated with 1.5 lg/ml of
doxorubicin for 24 h, while Fig. 7b depicts the culture
treated for the same period with the same concentration of
doxorubicin but complexed with the BTNPs (Dox–BTNPs
at 15 lg/ml): the increment in red fluorescence in the cells
0
0.5
1
1.5
2
2.5
240 340 440 540 640 740 840
wavelength (nm)
ab
so
rb
an
ce
 (A
U
)
Doxorubicin
Dox-BTNP
Fig. 5 UV/Vis/NIR absorbance analysis of doxorubicin alone and
complexed with the nanoparticles (Dox–BTNP)
a
b
0
200
400
600
800
1000
1200
K A B C D
test
fl
u
o
re
sc
en
ce
 in
te
n
si
ty
 (
A
U
)
Dox
Dox-BTNP
*
* *
0
20
40
60
80
100
120
K A B C D
test
M
T
T
 v
al
u
e 
(%
)
Dox
Dox-BTNP
* *
**
Fig. 6 MTT test (a) and fluorescence quantitative uptake investiga-
tion (b) on the Dox–BTNPs complexes and on respective controls
(doxorubicin alone). * p \ 0.05, ** p \ 0.005
Nanoscale Res Lett (2010) 5:1093–1101 1099
123
is dramatic when the drug is combined with the nanopar-
ticles. These results corroborate the fluorescence quantifi-
cation previously presented.
All these data confirm an enhancement of the drug
uptake by the cells and therefore of the efficiency of
doxorubicin when complexed to the BTNPs, most probably
due to an increment in drug internalization favoured by the
nanoparticles uptake: TEM imaging, in fact, performed
after 24 h of incubation in a 15 lg/ml Dox–BTNP-modi-
fied medium, confirmed a strong internalization of Dox–
BTNPs in the cytoplasm of the SH-SY5Y cells, as shown
in Fig. 7c, where the strong-dark electron-dense BTNPs are
easily observable in the cells.
Conclusion
In this paper, we have presented two non-covalent
approaches for the stabilization of BTNPs in an aqueous
environment. Glycol-chitosan, thanks to its cytocompati-
bility and biological inertia, allowed highly concentrated
BTNP dispersions to be obtained that enabled us to extend
our previous investigations into BTNP cytotoxicity and to
demonstrate the absence of negative effects on cell cultures
following the treatment with high concentrations of BTNPs
(100 lg/ml).
Additionally, the functionalization with doxorubicin
demonstrated the possibility to obtain non-covalent supra-
molecular complexes, presumably thanks to hydrophobic
interactions between the nanoparticle surface and the aro-
matic rings of the drug. The internalization by the neuro-
blastoma cells of the drug by exploiting such complexes
resulted significantly higher than that obtained using mere
doxorubicin solution. Dox–BTNP complexes exhibited
considerably enhanced cytotoxic activity when compared
to that of doxorubicin alone.
Similar results were recently achieved by other groups
with carbon nanotubes [27, 28]. However, we would like to
stress that: (i) in our system, we do not require additional
surfactants to stabilize the nanostructures and doxorubicin
acts per se as a stabilizing agent, thus potential toxicity due
to high concentration of surfactant is completely avoided;
Fig. 7 SH-SY5Y culture incubated for 24 h with 1.5 lg/ml of doxorubicin (a) and culture treated for the same period with the same
concentration of doxorubicin but complexed with the BTNPs (Dox–BTNPs 15 lg/ml (b); TEM imaging on Dox–BTNPs-treated cells (c)
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(ii) the concerns about cytotoxicity of carbon nanotubes are
not yet fully addressed in the literature that often offers
contrast conclusions [29, 30], hence the necessity to find
alternative suitable nanomaterials. Although several
investigations are still due, collectively, our results on
BTNPs suggest that they can concur in several biomedical
applications, as a valid alternative to the currently inves-
tigated nanoplatforms.
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